ECB Signals Possible Interest Rate Move if Inflation Outlook Fails to Improve 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
